Advanced Y2H Screening Service for Drug-Target Interaction Identification

Background Service Workflow Application Advantage Related Services FAQ Online Inquiry

Identifying the specific protein targets of small molecules is a critical yet challenging step in drug discovery and chemical biology. For over two decades, Creative Biolabs has been at the forefront of protein interaction analysis. We have refined the powerful Yeast Two-Hybrid (Y2H) technology into a sophisticated, high-throughput platform specifically designed for unbiased drug-target interaction identification. Our next-generation Y2H-based services provide a robust, in vivo solution to decipher the direct protein interactions of your small molecule, compound, or drug candidate.

Discuss Your Project Today

The Challenge: From Phenotypic Hit to Molecular Target

Phenotypic drug discovery has yielded numerous first-in-class therapeutics, yet a significant bottleneck remains: identifying the specific protein target(s) responsible for the observed biological effect. Traditional methods like affinity chromatography can be hampered by low-affinity interactions, non-specific binding, and challenges in protein elution and identification. A failure to accurately identify a drug's targets can lead to:

Incomplete MoA Understanding: Slowing down lead optimization and clinical development.
Unforeseen Toxicity: Arising from unknown off-target interactions.
Missed Opportunities: Overlooking novel therapeutic applications (drug repositioning).

Harnessing the Power of Yeast Two-Hybrid for Drug-Target Discovery

The Yeast Two-Hybrid (Y2H) system is a premier genetic method for detecting protein-protein interactions in vivo. At Creative Biolabs, we have ingeniously adapted this technology to identify interactions between a small molecule and its protein targets.

Our platform is built on a modified Y3H/chemical-induced dimerization principle. The system consists of three key components:

The "Bait": Your small molecule is chemically conjugated to a known protein-binding molecule (e.g., FKBP), which is then fused to the DNA-Binding Domain (DBD) of a transcription factor (like GAL4).
The "Prey": A vast library of potential target proteins (from human, mouse, or other species) is fused to the Activation Domain (AD) of the transcription factor.
The Reporter System: In yeast cells, if your small molecule (bait) interacts with protein from the library (prey), the DBD and AD are brought into proximity. This reconstitution of the transcription factor activates the expression of reporter genes, leading to a detectable signal (e.g., cell growth on selective media).

Fig. 1 Schematic representation of Y2H based drug-target interaction identification. (Creative Biolabs Original). Fig. 1 Drug-target interaction identification or screening based on the Y2H system.

Next-Generation Y2H Screening Service: Precision, Depth, and Reliability

We have integrated the latest technologies to create a state-of-the-art Y2H based drug-target interaction identification platform that ensures maximum coverage and minimal false positives.

Key Features of Our Platform

Unparalleled Library Diversity

Screen against our highly complex, ready-to-use human and mouse cDNA/ORF libraries, covering millions of independent clones to ensure a comprehensive search for your drug's targets. Custom library construction is also available.

Expert Bait Design and Validation

Our scientists possess deep expertise in the crucial first step: designing and synthesizing a high-affinity, specific bait construct. Every bait is rigorously tested for auto-activation and toxicity to ensure clean screening results.

Next-Generation Sequencing (NGS) for Hit Identification

Moving beyond traditional colony picking, we employ NGS to sequence all positive hits from the screen. This powerful approach allows us to:

Detect low-abundance interactors.
Eliminate common false positives.
Quantify the relative abundance of each interacting protein.
Provide a comprehensive, unbiased dataset of potential targets.

Specialized Systems for Challenging Targets

We offer modified Y2H systems, such as our split-ubiquitin Y2H (MYTH), specifically designed to identify interactions involving membrane proteins (e.g., GPCRs, ion channels), a notoriously difficult but vital class of drug targets.

Rigorous Data Analysis

You receive more than just a list of hits. Our comprehensive report includes bioinformatics analysis, functional annotation, and a ranked list of high-confidence candidate targets to guide your next steps.

Our Streamlined Path to Your Drug's Target Profile

Creative Biolabs offers an end-to-end service, managing every step of the process with transparency and expert oversight.

Our Workflow Includes:

Initial Consultation: Our Ph.D.-level specialists work with you to understand your compound and research goals to design the optimal screening strategy.
Bait Conjugate Synthesis and QC: We handle the chemical linkage of your small molecule to the bait protein and perform rigorous quality control.
High-Throughput Y2H Screening: Your bait is screened against the selected high-complexity library under stringent conditions.
Hit Identification and Confirmation: Positive colonies are isolated, and the interacting prey proteins are identified using high-throughput NGS.
Data Analysis and Reporting: A detailed report is delivered, including the primary sequence of all identified targets, hit ranking, and in-depth bioinformatics analysis to place the targets in a biological context.

Driving Drug Discovery Forward: Key Applications

Our Y2H based Drug-Target Interaction Identification Service is a versatile tool that can be applied across the drug discovery pipeline to provide actionable insights.

Novel Target Identification: Directly identify the molecular target(s) of compounds discovered through phenotypic screening.
Mechanism of Action (MoA) Elucidation: Confirm on-target engagement and uncover the full biological pathways modulated by your drug candidate.
Off-Target Profiling & Safety Assessment: Proactively identify unintended targets to predict potential side effects and toxicity early in the development process.
Drug Repositioning and Repurposing: Discover novel indications for existing drugs or clinical candidates by revealing previously unknown protein interactions.
Biomarker Discovery: Identify proteins whose interaction with a drug can serve as a predictive biomarker for efficacy or patient stratification.

The Creative Biolabs Advantage: Your Partner in Target Discovery

Choosing Creative Biolabs means partnering with a leader in protein interaction science.

Over 20 Years of Expertise: Our long-standing focus on Y2H and other interaction technologies gives us an unparalleled depth of knowledge to tackle even the most challenging projects.
Cutting-Edge Integrated Technologies: Our investment in NGS and proprietary Y2H system modifications ensures you receive the most sensitive and accurate data possible.
Scientific Rigor: We are committed to minimizing false positives and negatives through stringent QC and multi-step validation processes.
End-to-End Support: From initial project design to providing a clear roadmap for downstream validation, our team supports you at every stage.
Customized Solutions: We understand that every project is unique. We offer flexible solutions, including custom library screening and validation strategies tailored to your specific needs.

Explore Our Related Protein-protein Interaction Services

Identifying a drug-target interaction with Y2H is a critical discovery. Creative Biolabs provides a comprehensive suite of downstream services to validate and characterize these interactions, providing the orthogonal data required for confident decision-making. Explore our full range of PPI services here: Protein-Protein Interaction (PPI) Assay Services

Let Creative Biolabs empower your drug discovery program with definitive Y2H based drug-target interaction identification.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQ)

Q: What types of small molecules are suitable for this Y2H screening service?

A: Our platform is highly versatile and can be adapted for a wide range of small molecules, including synthetic compounds, natural products, fragments, and metabolites. The primary requirement is that the molecule must possess a functional group (e.g., -OH, -NH2, -COOH, -SH) that allows for stable chemical conjugation to our bait scaffold. We recommend providing 5-10 mg of your compound for the entire process, including conjugation, quality control, and screening. Our chemistry team can provide a feasibility assessment before initiating the project.

Q: How does Creative Biolabs minimize and handle false positives?

A: This is a critical aspect of any screening service, and we have implemented a multi-layered strategy to ensure the highest data quality. Our approach includes:

Rigorous Bait QC: Before screening, every bait construct is tested for auto-activation of the reporter genes in the absence of a prey protein. Any auto-activating baits are re-engineered or excluded.
Stringent Selection Conditions: We utilize multiple reporter genes (e.g., HIS3, ADE2, lacZ) with varying stringencies to filter out weak or non-specific interactions.
NGS-Based Analysis: Unlike traditional methods, our Next-Generation Sequencing (NGS) approach identifies and quantifies all interacting partners. This allows us to computationally filter out known, promiscuous "false positive" proteins that frequently appear in Y2H screens and to prioritize hits based on abundance and statistical significance.
Orthogonal Validation Roadmap: We provide clear recommendations for downstream validation using non-Y2H methods (e.g., SPR) to confirm the biological relevance of high-confidence hits.

Q: Can this service be used to identify targets for membrane proteins?

A: Yes. While standard Y2H systems are limited to cytosolic and nuclear protein interactions, we offer a specialized Membrane Yeast Two-Hybrid (MYTH) system, also known as the split-ubiquitin system. This platform is specifically engineered to detect interactions involving integral membrane proteins, such as GPCRs, ion channels, and transporters, in their native membrane environment. Please specify if you anticipate your target to be a membrane protein during the initial consultation.

Q: What do I need to provide to start a project?

A: To begin, we typically require:

Approximately 5-10 mg of your small molecule compound.
Any known information about the compound's structure, stability, and solubility.
Your primary research objectives (e.g., MoA elucidation, off-target profiling).

Our team will handle the rest, starting with a confidential discussion to outline a tailored project plan that meets your specific scientific goals.

Reference

Scott, Louis H., et al. "Genetically encoded whole cell biosensor for drug discovery of HIF-1 interaction inhibitors." ACS Synthetic Biology 11.10 (2022): 3182-3189. https://doi.org/10.1021/acssynbio.2c00274

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.